Single shot Johnson & Johnson Covid vaccine recommended for FDA authorisation
If approved by FDA it would become the third vaccine authorised for emergency use in US
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The single shot Johnson & Johnson Covid vaccine has been recommended by experts for Food and Drug Administration authorisation.
The unanimous recommendation on Friday paves the way for the FDA to fully approve the vaccine, making it the third one available in the US.
If the FDA signs off on it this weekend, millions of doses of the vaccine, which does not need specialist cold storage, could be available across the country next week.
The rollout of a third vaccine comes as the US has just passed 500,000 deaths during the pandemic.
To date, only vaccines by Pfizer and Moderna have been approved for emergency use in the US by federal authorities and a third would help health officials speed up the rate of vaccination.
Earlier this week Joe Biden marked the country passing the 50 million vaccinations, and the president has vowed to vaccinate 100 million people in his first 100 days in office.
Johnson & Johnson is expected to ramp up production of the vaccine, if approved, and plans to deliver 20 million doses by the end of March.
The company’s data shows that their vaccine was 72 per cent effective at preventing cases of moderate to severe Covid-19 in the US.
The firm also stated to the FDA that the vaccine was 85 per cent effective in preventing severe cases of Covid-19.
The US government has already ordered 100 million doses of the vaccine at a cost of $1.5bn, all of which would be delivered by the end of June.
The first two vaccines were given the green light by officials in December and the president has said that everyone in the country who wants the vaccine will have it by the end of July.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments